Kazia Therapeutics Regains Nasdaq Compliance, Strengthening Oncology Pipeline and Investor Confidence

Kazia Therapeutics Regains Compliance with Nasdaq Listing Standards, Strengthening Oncology Pipeline

Kazia Therapeutics Limited, a Sydney-based clinical-stage oncology company, announces a significant milestone as it regains full compliance with Nasdaq's listing standards. The company meets the $2.5 million minimum stockholders' equity requirement, as confirmed by Nasdaq on December 18, 2025. This development leads to the cancellation of a scheduled hearing before the Nasdaq Hearings Panel, a situation that indicates the company’s financial health and operational stability. The restoration of compliance comes on the heels of a successful $50 million private placement of equity securities, which has greatly enhanced Kazia's balance sheet and solidified its stockholders’ equity position.

Dr. John Friend, CEO of Kazia, emphasizes the importance of this achievement, noting that it reflects the company's financial strengthening and positions Kazia favorably to advance its clinical programs. The reinstatement of Nasdaq compliance not only bolsters investor confidence but also enhances Kazia's flexibility in the capital markets. This newfound stability allows the company to focus on its core mission of developing innovative therapies for cancer, particularly through its clinical-stage pipeline.

Kazia is actively advancing its promising drug candidate, paxalisib, which is undergoing a Phase 1b clinical trial. This therapy, a brain-penetrant pan-PI3K/mTOR inhibitor, is being evaluated for its effectiveness in combination with checkpoint inhibitors and chemotherapy for patients suffering from advanced triple-negative breast cancer. The company’s commitment to developing treatments for significant unmet needs in cancer care underscores its strategic focus and dedication to improving patient outcomes.

In addition to regaining compliance, Kazia's recent financial success provides a robust foundation for further clinical development. The company's innovative approach and focus on challenging cancers position it as a key player in oncology. With the reinstatement of Nasdaq compliance, Kazia is poised to navigate the complexities of the capital market while pursuing breakthroughs in cancer treatment.